Cargando…
Immunomodulation with Recombinant Interferon-γ1b in Pulmonary Tuberculosis
BACKGROUND: Current treatment regimens for pulmonary tuberculosis require at least 6 months of therapy. Immune adjuvant therapy with recombinant interferon-γ1b (rIFN-γb) may reduce pulmonary inflammation and reduce the period of infectivity by promoting earlier sputum clearance. METHODOLOGY/PRINCIPA...
Autores principales: | Dawson, Rod, Condos, Rany, Tse, Doris, Huie, Maryann L., Ress, Stanley, Tseng, Chi-Hong, Brauns, Clint, Weiden, Michael, Hoshino, Yoshihiko, Bateman, Eric, Rom, William N. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2737621/ https://www.ncbi.nlm.nih.gov/pubmed/19753300 http://dx.doi.org/10.1371/journal.pone.0006984 |
Ejemplares similares
-
Increased Production of IL-4 and IL-12p40 from Bronchoalveolar Lavage Cells Are Biomarkers of Mycobacterium tuberculosis in the Sputum
por: Nolan, Anna, et al.
Publicado: (2013) -
Exogenous Interferon-α and Interferon-γ Increase Lethality of Murine Inhalational Anthrax
por: Gold, Jeffrey A., et al.
Publicado: (2007) -
Maximal HIV-1 Replication in Alveolar Macrophages during Tuberculosis Requires both Lymphocyte Contact and Cytokines
por: Hoshino, Yoshihiko, et al.
Publicado: (2002) -
Effect of liposome-encapsulation on immunomodulating and antiviral activities of interferon-γ()
por: Saravolac, E.G., et al.
Publicado: (1996) -
Lung microbiome and host immune tone in subjects with idiopathic pulmonary fibrosis treated with inhaled interferon-γ
por: Wang, Jing, et al.
Publicado: (2017)